The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KPTI | -51.89% | -97.4% | -51.82% | -97% |
| S&P | +15.06% | +95.03% | +14.29% | +280% |
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
The company downgraded guidance in its first-quarter report.
The company's second-quarter performance had some highlights, but investors might have been concerned about full-year guidance.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $37.93M | -11.4% |
| Gross Profit | $36.80M | -10.7% |
| Gross Margin | 97.02% | 0.7% |
| Market Cap | $37.24M | -63.1% |
| Market Cap / Employee | $0.13M | 0.0% |
| Employees | 279 | -14.2% |
| Net Income | -$37.25M | -256.6% |
| EBITDA | -$24.31M | 13.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $38.73M | -54.3% |
| Accounts Receivable | $32.93M | -13.3% |
| Inventory | 5 | 43.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $158.50M | -17.5% |
| Short Term Debt | $32.12M | 806.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -77.51% | -42.4% |
| Return On Invested Capital | -50.60% | 116.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.70M | 51.4% |
| Operating Free Cash Flow | -$18.70M | 51.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.65 | -0.46 | -0.17 | -0.18 | -70.00% |
| Price to Sales | 0.70 | 0.59 | 0.22 | 0.27 | -70.57% |
| Price to Tangible Book Value | -9.77 | -7.96 | -0.17 | -0.18 | -98.00% |
| Enterprise Value to EBITDA | -6.28 | -5.48 | -4.47 | -7.24 | 14.41% |
| Total Debt | $194.26M | $194.52M | $186.70M | $190.62M | -2.56% |
KPTI earnings call for the period ending December 31, 2024.
KPTI earnings call for the period ending September 30, 2024.
KPTI earnings call for the period ending June 30, 2024.
KPTI earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
